Tu WJ, Qiu HC, Zhang Y, et al. Lower serum retinoic acid level for prediction of higher risk of mortality in ischemic stroke. Neurology. 2019;92(15):e1678–87.
The GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379:2429–37.
Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179–88.
Pessin JE, Kwon H. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. 2013;4:71.
Lopez-Jaramillo P. The role of adiponectin in cardiometabolic diseases: effects of nutritional interventions. J Nutri. 2016;146(2):422S–6S.
Sun L, Liu X. Functions of adiponectin signaling in regulating neural plasticity and its application as the therapeutic target to neurological and psychiatric diseases. Rev Neurosci. 2019;30(5):485–95.
Bloemer J, Pinky PD, Govindarajulu M, et al. Role of adiponectin in central nervous system disorders. Neural Plasticity. 2018. https://doi.org/10.1155/2018/4593530.
Menzaghi C, Trischitta V. The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes. 2018;67(1):12–22.
Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem. 2010;285:6153–60.
Hu J, Li J, Liang L, et al. Abstract P049: circulating adiponectin levels and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality in US women. Circulation. 2019;139:AP049.
Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599–606.
Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756–62.
Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J. 2006;27:2300–9.
Poehls J, Wassel CL, Harris TB, Havel PJ, Swarbrick MM, Cummings SR, et al. Association of adiponectin with mortality in older adults: the health, aging, and body composition study. Diabetologia. 2009;52:591–5.
Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infarction: a paradox or a paradigm? Eur Heart J. 2006;27:2266–8.
Hao G, Li W, Guo R, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis. 2013;228(1):29–35.
Yang J, Du G, Wang J, et al. Reduced serum adiponectin level and risk of poststroke depression in patients with ischemic stroke. J Stroke Cerebrovascular Dis. 2019;28(2):305–10.
Ilhan N, Susam S, Canpolat O, et al. The emerging role of leptin, Adiponectin and Visfatin in Ischemic/Hemorrhagic stroke. Br J Neurosurg. 2019;33(5):504–7.
Kanhai DA, Kranendonk ME, Uiterwaal C, et al. Adiponectin and incident coronary heart disease and stroke A systematic review and meta-analysis of prospective studies. Obesity Rev. 2013;14(7):555–67.
Arregui M, Buijsse B, Fritsche A, et al. Adiponectin and risk of stroke: prospective study and meta-analysis. Stroke. 2014;45(1):10–7.
Efstathiou SP, Tsioulos DI, Tsiakou AG, et al. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke. 2005;36(9):1915–9.
Sook Lee E, Park S, Kim E, et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol. 2013;42(4):1029–39.
Liberale L, Carbone F, Bertolotto M, et al. Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis. Vascul Pharmacol. 2018;102:37–43.
Zeng X, Deng A, Ding Y, et al. Copeptin and NT-proBNP as prognostic markers for recurrent ischemic cerebrovascular events in ischemic stroke patients. J Am Coll Cardiol. 2016;68(24):2710–1.
Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–70.
Tu WJ, Ma GZ, Ni Y, et al. Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke. Neurology. 2017;88(20):1899–905.
Witberg G, Ayers CR, Turer AT, et al. Relation of adiponectin to all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (from the Dallas Heart Study). Am J Cardiol. 2016;117(4):574–9.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
Li X, Guo H, Zhao L, et al. Adiponectin attenuates NADPH oxidase-mediated. Biochimica et Biophysica Acta. 2017;1863(12):3265–76.
Kizer JR, Benkeser D, Arnold AM, et al. Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation. 2012;126(25):2951–61.
Kuwashiro T, Ago T, Kamouchi M, et al. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke—Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism. 2014;63(9):1093–103.
Nagasawa H, Yokota C, Toyoda K, et al. High level of plasma adiponectin in acute stroke patients is associated with stroke mortality. J Neurol Sci. 2011;304(1–2):102–6.
Carbone F, Burger F, Roversi G, Tamborino C, Casetta I, Seraceni S, Mach F. Leptin/adiponectin ratio predicts poststroke neurological outcome. Eur J Clin Invest. 2015;45(11):1184–91.
Wang Z, Li B, Wang Y, Maimaitili A, Qin H, Dangmurenjiafu G, Wang S. The association between serum adiponectin and 3-month outcome after ischemic stroke. Cardiovascu Diabetol. 2019;18(1):105.
Schrieks IC, Nozza A, Stähli BE, et al. Adiponectin, free fatty acids, and cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome. Diab Care. 2018;41(8):1792–800.
Forsblom C, Thomas MC, Moran J, et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med. 2011;270(4):346–55.
Singer JR, Palmas W, Teresi J, et al. Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diab Care. 2012;35(9):1858–63.
Hascoet S, Elbaz M, Bongard V, et al. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol. 2013;33(1):e19–29.
Lindberg S, Mogelvang R, Pedersen SH, et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol. 2013;111(8):1139–45.
Wu ZJ, Cheng YJ, Gu WJ, et al. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism. 2014;63(9):1157–66.
Ritsinger V, Brismar K, Malmberg K, et al. Elevated levels of adipokines predict outcome after acute myocardial infarction: a long-term follow-up of the glucose tolerance in patients with acute myocardial infarction cohort. Diab Vascu Dis Res. 2017;14(2):77–87.
Sasso FC, Pafundi PC, Marfella R, Calabrò P, Piscione F, Furbatto F, Salvatore T. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovascu Diabetol. 2019;18(1):24.
Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(1):134–41.
Jeon JY, Ha KH, Han SJ, et al. Blood adiponectin levels are not associated with risk of cardiovascular events in patients with type 2 diabetes. Diab Vascular Dis Res. 2018;15(6):571–5.
Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006;114:623–9.
Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol. 2007;165:164–74.
Scarale MG, Fontana A, Trischitta V, et al. Circulating adiponectin levels are paradoxically associated with mortality rate: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;104(5):1357–68.
Drechsler C, Krane V, Winkler K, et al. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int. 2009;76(5):567–75.
Wannamethee SG, Welsh P, Whincup PH, et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovascu Prevent Rehab. 2011;18(1):65–71.
Masuch A, Pietzner M, Bahls M, et al. Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP. Cardiovascu Diabetol. 2018;17(1):120.
Menzaghi C, Xu M, Salvemini L, et al. Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol. 2014;13:130.
Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F, MMKD Study Group. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int. 2007;71:1279–86.
Prugger C, Luc G, Haas B, et al. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol. 2012;71(4):478–86.
Bidulescu A, Liu J, Chen Z, et al. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in African Americans: the Jackson Heart Study. Front Public Health. 2013;1:16.
Wu P, Wen W, Li J, et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. Horm Metab Res. 2019;51(08):487–94.
Chruściel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208.
Katsiki N, Mantzoros CS. Statins in relation to adiponectin: a significant association with clinical implications. Atherosclerosis. 2016;253:270–2.
Liu X, Men P, Wang Y, et al. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids Health Dis. 2016;15(1):1–9.
Khan RS, Kato TS, Chokshi A, et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail. 2012;5:340–8.
Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009;53:2070–7.
Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–63.
Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept. 2006;134:105–13.
Une K, Takei YA, Tomita N, Asamura T, Ohrui T, Furukawa K, Arai H. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer’s disease. Eur J Neurol. 2011;18:1006–9.
Gairolla J, Kler R, Modi M, et al. Leptin and adiponectin: pathophysiological role and possible therapeutic target of inflammation in ischemic stroke. Rev Neurosci. 2017;28(3):295–306.
Wu DM, Wang S, Wen X, et al. Impact of serum omentin-1 levels on functional prognosis in nondiabetic patients with ischemic stroke. Am J Transl Res. 2019;11(3):1854–63.
Zhu Y, Zhang J, Liu L, et al. Evaluation of serum retinol-binding protein-4 levels as a biomarker of poor short-term prognosis in ischemic stroke. Biosci Rep. 2018. https://doi.org/10.1042/BSR20180786.
Tu WJ, Zeng XW, Deng A, et al. Circulating FABP4 (fatty acid–binding protein 4) is a novel prognostic biomarker in patients with acute ischemic stroke. Stroke. 2017;48(6):1531–8.
Nishimura M, Morioka T, Hayashi M, Kakutani Y, Yamazaki Y, Kurajoh M, Inaba M. Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study. Cardiovascu Diabetol. 2019;18(1):167.
Moreno LO, Copetti M, Fontana A, et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovascu Diabetol. 2016;15(1):17.